FDA Approvals: New agent for chronic myeloid leukemia

The FDA has approved bosutinib as a new treatment option for adult patients with previously treated Philadelphia chromosome–positive (Ph+) CML. The approval was based on the efficacy and safety data from Study 200, a single-group study of bosutinib that enrolled 571 patients with previously treated Ph+ CML, including those resistant or intolerant to imatinib as well as patients who were previously treated with dasatinib or nilotinib. More information about Bousutinib can be found from FDA website here.